OCT 31, 2018 9:02 AM PDT

Cytostatic Drug Proved Potent For Cancer

WRITTEN BY: Nouran Amin

Image via ArcoMed

A study published in journal Angewandte Chemie, describes how a cytostatic drug, consisting of therapeutically active molecules that is linked to specific antibodies can treat tumors. Such novel conjugates are made from antibodies and a protein that inhibits kinesin spindle formation.

The study revealed that changing the “linkage” between these two components allows for the drugs cytostatic activity in a broad palette of cancers.

The purpose of the study was to introduce a new cytostatic drug that will not produce adverse effects on cancer patients. This is especially true since many medications may be effective but interfere with physiological regulatory mechanisms that cause the impairment of immune defenses, produce hair loss, and induce nausea.

Watch the short video below on side-effects of chemotherapeutic drugs:

The study was aimed at introducing a cytostatic drug directly into tumor cells before triggering a toxic effect. One proposed way was to attach small drug molecules to an antibody (that binds to specific sites—antigens) and produce a conjugate.

The linker will serve as a bridging component that will hold the conjugate together for as long as it circulates in the blood. Although incorporating cytostatic drugs into antibody conjugates have been so far successful, they are limited.

Diverging away from the classic mechanisms of cytostatic drugs, researchers have opted to use cytotoxin that which that utilizes a different biological pathway. More specifically, the cytotoxin is a novel pyrrole-based kinesin spindle protein (KSP) inhibitor which is implicated centrosome separation during cell division. Low doses of this cytoxin is highly effective enough to inhibiting this step of the cell cycle leading to a strong antitumor effect. The researchers have demonstrated that use of this technique can produce a highly effective antibody conjugates that allow them to target a variety of tumor types.

Image Credit: Wiley Online Libraries

The developed conjugates were seen to be very potent in vitro and when using experiments on mice, the conjugates led to complete remission of a human bladder tumor model with minimal side effects

Source: Wiley

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
DEC 15, 2019
Microbiology
DEC 15, 2019
Potential Therapeutics for Nipah Virus Are Identified
The fatality rate of Nipah virus has an estimated range of 40 to 75 percent...
JAN 09, 2020
Drug Discovery & Development
JAN 09, 2020
Can Cancer Drugs Treat Lung Damage?
Can therapeutics used in the treatment of cancer be a breakthrough for pulmonary disease? Specifically, chronic obstructive pulmonary disease (COPD)? &ldqu...
JAN 15, 2020
Cancer
JAN 15, 2020
Hope for patients with AML
Research published recently in the medical journal EMBO Molecular Medicine brings hope for leukemia patients with a report that a common and cheap drug may...
JAN 22, 2020
Cannabis Sciences
JAN 22, 2020
Antibiotic Properties Found in Cannabis Compound
The World Health Organization has identified antibiotic resistance, when bacteria no longer respond to antibiotics, as one of the biggest threats to global...
FEB 08, 2020
Drug Discovery & Development
FEB 08, 2020
Drug Targets Brain-Eating Amoebas
Brain-eating amoebas lead to high rates of mortality as a result of encephalitis. In fact, more than 95% of people who develop the infection will die. Unfo...
Loading Comments...